Kornimate/medical-research-clean huggingface dataset:
management of mixed-phenotype acute leukemia in the east of france

Conditions: Mixed Phenotype Acute Leukemia

Summary: clinical presentation and management of mixed-phenotype acute leukemia (mpal) is heterogeneous. this descriptive observationnal study aims to review mpal cases in the east of france based on a 10-year multicentre retrospective collection.


Eligibility criteria:
inclusion criteria: * adult patients over 18 years of age * diagnosis of biphenotypic acute leukemia or mixed-phenotype acute leukemia between 2008 and 2018
comparison of supraglottic airway devices in ebus

Conditions: Airway Management; Lung Diseases

Summary: supraglottic airway devices (sad) provide ventilation of patients requiring respiratory support without tracheal intubation. therefore, sad is used to maintain airway during anesthesia in surgeries that do not require intubation. the classical laryngeal mask (clma, intavent direct, maidenhead, uk) is an sad that is available as a more advanced airway method than mask ventilation and a less invasive method than endotracheal intubation. it is used by placing it over the glottis at the level of the larynx and inflating the cuff. the proseal laryngeal mask (lma-proseal™, plma, intavent orthofix, maidenhead, uk) is the first supraglottic airway device that is suitable for reuse and includes a gastric drainage channel. i-gel™ (intersurgical ltd, wokingham, uk) is a second-generation laryngeal mask with a soft, gel-like thermoplastic elastomer distal end and no inflatable cuff, designed not to compress the anatomical structures of the larynx and pharynx. endobronchial ultrasound (ebus)-guided transbronchial needle aspiration (tbna) has become one of the most important invasive diagnostic procedures for pulmonologists and thoracic surgeons. it is a safe and effective technique for sampling hilar and mediastinal lymph nodes and masses. it is currently accepted as the first choice for histological sampling of the mediastinum in lung cancer staging. the use of sad to secure the airway in patients undergoing ebus-tbna has the advantages of being less invasive than endotracheal intubation and providing better surgical field access. classical lma, proseal lma and i-gel are routinely used airway methods during ebus-tbna procedure. the aim of this study is to compare the routinely used sads in anesthesia management in patients undergoing endobronchial ultrasonography-guided transbronchial needle aspiration in terms of intraoperative efficacy and postoperative complications.

the parameters to be recorded are: demographic characteristics of the patients, hemodynamic data during and after the procedure, ventilation variables (tidal volume, airway pressures, leak volume), the number of attempts to place the sad, the need for intubation, the presence of sore throat, nausea and vomiting after the procedure. in addition, the operator performing the procedure will be asked to evaluate the convenience of the procedure.

Eligibility criteria:
inclusion criteria: * adults ageing 18-80 years * patients in asa phyical class * patients undergoing endobronchial ultrasound guided transbronchial needle aspiration exclusion criteria: * patients undergoing emergent procedure * pediatric patients * patients having upper airway pathology * patients in risk of aspiration

Keywords: airway management lung diseases
anterior cruciate ligament reconstruction made with hamstring tendon and quadriceps tendon autografts

Conditions: Anterior Cruciate Ligament Injuries

Summary: anterior cruciate ligament reconstruction (aclr) is one of the most common procedure all around the world, however optimal graft source for aclr still remains controversial. although quadriceps tendon (qt) is the least used and least studied autograft, it could be an appropriate and good alternative for aclr. if investigaters use the same surgical technique, and exert the same rehabilitation methods they may have better results than hamstring tendon (ht) autografts.

investigators enrolled 36 patient and randomized them to different group (ht, qt). at the first evaluation examination findings noted, proms (patient reported outcome measurements) questioned, thigh circumference measured, flexor and extensor thigh muscle strength recorded with help of humac cybex norm (csmi, 2004) device. after these examinations and preparations all patients operated by the same surgeon who is familiar with both technique. the same surgical technique and fixation method used for both groups. at 1st year follow-up all evaluations proms (i̇kdc,lysholm,vas) and measurements repeated. back to the sports rates and postoperative complications compared between ht-qt.

Eligibility criteria:
inclusion criteria: diagnosed primary acl rupture willing to involve study * lesser than outerbridge 2 cartilage lesions, non-buckethandle meniscus injuries exclusion criteria: more than one ligament injury greater than outerbridge 3 cartilage injury buckethandle meniscus injuries re-ruptures bilateral injuries previous knee surgery any disease affecting muscle strength -
retrospective epidemiological study of locally advanced non small cell lung cancer patients in brazil

Conditions: Lung Cancer, Non-small Cell

Summary: relance is a large multi-institutional study that aims to retrospectively collect information about diagnostic, treatment and outcome of patients diagnosed with locally advanced nsclc in brazil. it is hypothesized that there is a great heterogeneity in treatment patterns owing to inequities in access to adequate staging methods, optimal treatment and multidisciplinary teams in brazil.

relance study will collect sociodemographic and clinical data of patients diagnosed with locally advanced nsclc in the period of january 2015 and jun 2019 in the participating institutions. socio-demographic characteristics, clinicopathological features, treatments patterns and outcomes will be recovered from medical charts. disease status and survival data will be collected up to the last date of follow-up june 2021.

Eligibility criteria:
inclusion criteria: 1. patients aged 18 years or older; 2. histologically or cytological diagnosis of nsclc in the period of january 2015 to december 2016; 3. locally advanced nsclc defined as clinical stage iiia and iiib according to 7th edition tnm staging system; 4. any nsclc histological subtype and molecular mutation; 5. any eastern cooperative oncology group (ecog) performance status (0 to 4) at diagnosis; 6. patients assigned by treating physician to any therapy or palliative care; 7. access to patient medical chart for data collection. exclusion criteria: 1. small cell lung cancer and non-invasive nsclc; 2. synchronic nsclc or second primary tumour in the last 5 years (except non-melanoma skin cancer).

Keywords: lung cancer non-small cell
correlation between complications after pancreaticoduodenectomy and microbiota

Conditions: Pancreatic Cancer

Summary: pancreaticoduodenectomy is the most performed pancreatic surgery for malignant or premalignant tumors of the region of the head of the pancreas. its post-operative morbidity is very high, over 40%. there is very little data on the impact of microbiota on complications after pancreatic surgery. the purpose of this research is to study the correlation between the microbiota (fecal, blood, oral, biliary, pancreatic and intestinal microbiota) and the postoperative complications in patients who undergo pancreaticoduodenectomy.

after pancreaticoduodenectomy, the post-operative complications can be surgical (pancreatic fistula, gastroparesis) but also infectious, digestive (diarrhea) and lead to malnutrition. they are responsible for prolonged post-operative hospitalizations, impaired quality of life of patients and induce a delay in the implementation of adjuvant chemotherapy, or even an impossibility to achieve it. the absence of adjuvant chemotherapy adversely affects the prognosis of patients, by increasing the rate of recurrence and decreased survival. there is therefore a real oncological benefit in finding solutions to reduce the number and severity of these complications. a change in post-operative microbiota composition has been shown to play a role in the development of post-surgical anastomotic fistulas in colorectal cancer. despite their importance, there is very little data on the impact of microbiota on complications after pancreatic surgery. we postulate that microbiota variations could have an impact on early and late post-operative complications after pancreaticoduodenectomy. any patient hospitalized at the toulouse university hospital with an indication of a pancreaticoduodenectomy will be offered to participate in this study. microbiota analysis will be carried out on different samples: blood, stool and saliva samples will be collected during the surgery, between j5 and j10 (post-operative during hospitalization) and at 3 and 6 months after the surgery. bile, pancreatic and intestinal mucosa samples will only be collected during the surgery. complications will be collected throughout this study. this study will not create any additional constraints on patient management. the follow-up period will be 6 months. this follow-up period will be fixed for all patients included. the microbiota analyses will be centrally determined during the study.

Eligibility criteria:
inclusion criteria: * patient hospitalized at the toulouse university hospital with an indication of a pancreaticoduodenectomy * patient aged over 18 years old * patient having given his written consent * patient with social insurance coverage exclusion criteria: * patient for whom the pancreaticoduodenectomy was not realized (exploratory laparotomy or other surgery)

Keywords: microbiota microbiome pancreaticoduodenectomy pancreatic resection whipple procedure postoperative complications
autologous tumor-infiltrating lymphocyte injection(gt201) for treatment of patients with advanced lung cancer

Conditions: Adult; Lung Cancer

Summary: this study is a single arm, open design aimed at evaluating the safety and tolerability of autologous tumor-infiltrating lymphocyte (gt201 injection ) for treatment of patients with advanced lung cancer,while evaluating pharmacokinetic characteristics and efficacy assessment.


Eligibility criteria:
inclusion criteria: * 1. voluntarily join the study, signed informed consent form，willing and able to comply with the study protocol; * 2. age 18 to 70 years old; * 3. queue 1: late stage non-small cell lung cancer without driver genes that have failed first-line systemic treatment;queue 2: small cell lung cancer with first-line systemic treatment failure; * 4. eastern cooperative oncology group (ecog) performance status score of 0 or 1; * 5. expected survival time of ≥ 12 weeks; * 6. good function of vital organs; * 7. subjects entering this study due to disease progression must have an imaging record of disease progression before tumor sampling; * 8. at least one measurable target lesion that meets the definition of recist v1.1 after tumor sampling. exclusion criteria: * 1.patients with uncontrollable tumor-related pain as judged by the investigator; participants requiring analgesic medication must already have a stable analgesic regimen at the time of study entry; symptomatic lesions suitable for palliative radiotherapy should be completed prior to study entry; * 2.known mental illness, alcoholism, drug use or substance abuse; * 3.pregnant or lactating women; or women who are pregnant, breastfeeding, or planning to become pregnant within 1 year after cell infusion; * 4.those who have received other clinical trial drug treatment within 4 weeks before preconditioning by lymphodepletion,plan to participate in other clinical trial drug treatment during the study; * 5.the investigators determine that other conditions that make the patient not suitable for enrollment.
prospective study of the risk of bacteremia in directed cholangioscopic examination of the cbd

Conditions: Choledocholithiasis; Cholangiocarcinoma; Benign Stricture of Common Bile Duct

Summary: when a doctor performs endoscopic retrograde cholangiopancreatography "ercp" (endoscopy to examine the bile duct) a flexible tube is inserted into the mouth and into the stomach. the tube passes beyond the stomach and into an opening in the liver called the bile duct. another small flexible endoscope is inserted inside the ercp scope to directly visualize the bile duct to ensure that there are no cancers or stones in the bile duct and occasionally to take a sample from the bile duct. the purpose of our study is to examine wither performing this procedure can transmit bacteria from the bile duct to the main blood stream.

this is a prospective study to measure the frequency of bacteremia in patients undergoing ercp with direct cholangioscopic examination of the common bile duct "cbd". a blood culture will be drawn from patients prior to the procedure, 5 minutes after the procedure and 30 minutes after the procedure. the patient will be followed up for 7 days after procedure for fever and sepsis. the estimated sample size is 60 patients.

Eligibility criteria:
inclusion criteria: * 1- adult patients (18-80) who are undergoing ercp with direct cholangioscopic examination of the common bile duct to ensure the clearance of the common bile duct from stones. 2- adult patients (18-80) who are undergoing ercp with direct cholangioscopic examination of the common bile duct for stone removal. 3- adult patients (18-80) who are undergoing ercp with direct cholangioscopic examination of the common bile duct for tissue acquisition from the common bile duct mass. 4- adult patients (18-80) who are undergoing ercp with direct cholangioscopic examination of the common bile duct for tissue acquisition from common bile duct strictures. exclusion criteria: * 1- patients younger than 18 yrs old or older than 80 yrs. 2- pregnant patients. 3- patient with ascending cholangitis, pneumonia or urinary tract infection 4- patients who received antibiotics in the last 2 weeks prior to the procedure.

Keywords: ercp direct cholangioscopic examination of the common bile duct choledocholithiasis cholangiocarcinoma benign stricture of common bile duct
effectiveness of pit and fissure sealants in the prevention of dental caries

Conditions: Caries, Dental

Summary: this randomized clinical trial is aimed at testing the efficacy of pit and fissure sealants, in a current environmental context different from that of the seventies and eighties. it has a split mouth design. 4oo subjects are included and the duration of follow up is 2 years.

this randomized clinical trial is aimed at testing the efficacy of pit and fissure sealants, in a current environmental context different from that of the seventies and eighties. this study assesses the cost-effectiveness of sealants according to the individual caries risk. this study takes place in nice, marseille and paris (france) and the patients are to be enrolled both in the dental hospitals and in the private practice. in the hospitals, the subjects are recruited directly by the headmasters of the pediatric dentistry or public health departments in the three dental schools. in private practice, the head of the department of pediatric dentistry and / or public health dentistry, of each dental school chooses 4 to 6 private practitioners who are used to place dental sealants in their daily practice. they recruit the subjects among their own patients. the type of study corresponds to randomized clinical trial (split mouth design) in which the tooth is the statistical unit (one pair of molars considered for each included patient). this study has a direct benefit for individuals. the number of necessary subjects is 328; the sample size is 400. the follow-up duration is 2 years. the treatment is a pit and fissure sealant on one randomized tooth by pair of permanent molars (split mouth design). sealant material is set up in accordance with the usual practice of each practitioner. occlusal exams are conducted every 6 months. the effectiveness of dental sealants and the retention of sealing materials are statistically analyzed according to both the individual caries risk and the clinical protocol

Eligibility criteria:
inclusion criteria: * child over 6 years old * patient with at least one carie * patient with at least one pair of permanent molar: healthy or with equivalent injuries exclusion criteria: * not cooperating in care * not speaking french or english

Keywords: sealant pit child over 6 years old least
oral prednisone in treating lch of bone in childhood and adolescence

Conditions: Langerhans Cell Histiocytosis of Bone

Summary: langerhans cell histiocytosis (lch) of bone is a benign-tumor-like osteolytic lesion in childhood and adolescence, which is characterized by the aberrant activation of antigen presenting cells. rather than the multi-system involvements of lch, no standard or widely-accepted therapeutic regimens were established for lch of bone. in the previous clinical practice, several lch patients obtained remarkable pain relief after taking prednisone. therefore, the investigators aim to conducting a multi-center, open-labelled, randomized-controlled, phase ii study to investigate the efficacy and safety of oral prednisone in treating lch of bone in children and adolescents. the enrolled patients will be randomly recruited to the following groups: (1) oral prednisone \[test group); (2) regular observation \[control group\].


Eligibility criteria:
inclusion criteria: * pathological diagnosis of langerhans cell histiocytosis (lch) of bone; * single-system involvement (skeletal system); * no need of surgical intervention; * must be able to swallow tablets; * signing informed consent form. exclusion criteria: * multi-system involvements (≥2 systems, including bone, liver, spleen, hematologic system, central nerve system); * need of surgical intervention (e.g. pathological fracture and/or spinal cord compression) * glucocorticoid allergy; * immunodeficiency; * severe infection; * insulin dependent/independent diabetes; * having taken glucocorticoid in the past two weeks; * not capable of swallowing tablets; * without signed informed consent inform.

Keywords: langerhans cell histiocytosis bone single-system children adolescents
developping a a brain-controlled art app to ease residual symptoms of depression

Conditions: Depression

Summary: the study evaluate the effect of 10 neurofeedback sessions on the residual symptoms of depressive patients in partial remission.


Eligibility criteria:
inclusion criteria: * subjects aged 25 to 65 included * information and signed informed consent * patients with a diagnosis of major depressive episode in remission * madrs score between 14 and 22 * patients with residual symptoms as assessed by madrs items * no cognitive impairment. * right-handed exclusion criteria: * subjects with legal incapacity or limited legal capacity * subjects unlikely to cooperate with the study and/or poor cooperation anticipated by the investigator * pregnant women * subjects in the exclusion period of another study or is on the "national volunteer list". * subjects with another psychiatric pathology (bipolar mood disorder, psychosis, obsessive-compulsive disorder, addictive pathology, schizophrenia) * subjects under a protective measure such as guardianship or safeguard of justice.
intravenous esketamine on prevention of postoperative depression in patients undergoing cardiac surgery

Conditions: Postoperative Depression

Summary: esketamine is a general anesthetic with anti-depressant effects at subanaesthetic doses. this study hypothesized that intraoperative administration of ketamine would prevent or mitigate postoperative depressive symptoms in surgical patients.

single subanaesthetic doses of i.v. esketamine may significantly improve symptoms in psychiatric patients with major depression. in patients undergoing cardiac surgery, postoperative depressive symptoms are common. this study hypothesizes that low-dose esketamine has a preventive effect on postoperative depression. however, evidence in this aspect is insufficient. the purpose of this study is to investigate the effect of a subanaesthetic dose of ketamine on pod for patients undergoing cardiac surgery.

Eligibility criteria:
inclusion criteria: * 1:patients scheduled for heart surgery * 2:moderate to severe depressive symptom measured by the qualified psychiatric doctors * 3:over 18 years of age * 4:american society of anesthesiologists physical status i-iii exclusion criteria: * 1:history of epilepsy * 2:major depression disorder patients undergoing antidepressive therapy within 2 weeks * 3: psychiatric illness * 4: drug abuse * 5:history of allergy to esketamine * 6:hyperthyroidism * 7:patients can not cooperate with investigators on psychiatric assessments * 8:pregnant or breastfeeding woman * 9:refuse to sign informed consent.

Keywords: esketamine postoperative depression cardic surgey
official record of patients diagnosed with lymphangioleiomyomatosis (lam)

Conditions: Leiomyomatosis

Summary: pulmonary lymphoangioleiomyomatosis (lam) is a rare destructive lung disease typically affecting women of childbearing age. currently, there is no effective therapy for the disease and the prognosis is poor. in order to better study this disease, the national heart, lung, and blood institute (nhlbi) has developed a registry to keep an official record of patients diagnosed with lam. this research project will collect data from 6 health care centers as well as outside physicians. researchers hope to provide valuable information about the rate of lung destruction and quality of life in patients with lam. patients participating in this study will be followed for 5 years. tissue collected from these patients may contribute to the development of future studies on the disease processes of lam.

lam is a rare disease that predominantly affects women of child-bearing age. to study in more detail this rare disease, this multi-center project will establish a registry of persons with lam. by combining data from 6 centers and outside physicians, this study may yield valuable information regarding the rate of decline in pulmonary function and quality of life in individuals with lam. these patients will be followed over a five-year period. tissue collected from study participants may facilitate future studies into the molecular basis of lam.

Eligibility criteria:
informed consent must be obtained from the patient. patients must be female. patients must be age 18 or older. patients with prevalent and incident cases are eligible. patients with the presence or absence of underlying diagnosis or evidence of tuberous sclerosis complex (tsc) are eligible. patients must have a diagnosis of lam confirmed by any of the following criteria: lung biopsy (transbronchial, surgical, transthoracic) judged to be diagnostic by the tissue core pathologists; or biopsy of lymph node or other mass judged to be diagnostic by the tissue core pathologists; or high resolution ct scan of the chest which is judged to be diagnostic of lam with a high degree of certainty by all three of the expert radiologists making up the imaging core. patients may be enrolled in other protocols.

Keywords: progesterone pulmonary function tests pneumothorax oopherectomy high resolution ct tuberous sclerosis complex lymphangioleiomyomatosis (lam)